← Back to Screener
US Stock Screener
HomeScreensNewsWatchlist
...

Atea Pharmaceuticals, Inc. (AVIR) 10-Year Financial Performance & Capital Metrics

AVIR •
HealthcareBiotechnologyVaccines and Infectious Disease
AboutAtea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The company also develops AT-752, an oral purine nucleoside prodrug product candidate, which has completed Phase Ia clinical trial for the treatment of dengue; AT-777, an NS5A inhibitor; AT-787, a co-formulated, oral, pan-genotypic fixed dose combination of AT-527 and AT-777 for the treatment of hepatitis C virous (HCV); and AT-281, a pharmaceutically acceptable salt for the treatment or prevention of an RNA viral infection, including dengue fever, yellow fever, Zika virus, and coronaviridae viral infection, as well as Ruzasvir, an investigational oral, pan genotypic NS5A inhibitor for the treatment of chronic HCV infection. It has a license agreement with Merck & Co, Inc. for development and commercialization of ruzasvir for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.Show more
  • Revenue $0
  • EBITDA -$193M -17.6%
  • Net Income -$168M -23.9%
  • EPS (Diluted) -2.00 -22.7%
  • Gross Margin -
  • EBITDA Margin -
  • Operating Margin -
  • Net Margin -
  • ROE -33.88% -49.0%
  • ROIC -36.66% +38.9%
  • Debt/Equity 0.00 -13.5%
  • Interest Coverage -
Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

  • ✓Company is almost debt free
  • ✓Momentum leader: RS Rating 85 (top 15%)
  • ✓Trading near 52-week high
  • ✓Trading at only 0.9x book value

✗Weaknesses

  • ✗Weak Piotroski F-Score: 3/9
  • ✗Low asset turnover indicates capital-intensive operations

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-
5Y-
3Y-
TTM-

Profit (Net Income) CAGR

10Y-
5Y-
3Y-
TTM15.51%

EPS CAGR

10Y-
5Y-
3Y-
TTM14.49%

ROCE

10Y Avg-21.51%
5Y Avg-13.3%
3Y Avg-28.18%
Latest-38.26%

Peer Comparison

Vaccines and Infectious Disease
Select Columns
Size & Scale
Valuation
Per Share
Growth
Profitability
Quality & Returns
Safety & Leverage
TTM Growth
Famous Investor Metrics
Dividends
Latest Quarter
Momentum & Returns
Total Return (DRIP)
Technical
Volume & Trading
Shares & Dilution
Sector-Specific
NameMarket CapCurrent PriceP/E RatioRevenue Growth 1YNet MarginROEFCF YieldDebt/Equity
CVACCureVac N.V.1.05B4.666.478.96%37.93%33.02%7.95%0.06
NVAXNovavax, Inc.1.67B10.143.9364.69%39.19%
SCNIScinai Immunotherapeutics Ltd.3.03B0.890.15401.83%58.65%0.21
TNXPTonix Pharmaceuticals Holding Corp.142.05M13.97-0.0829.94%-9.63%-42.93%0.04
INOInovio Pharmaceuticals, Inc.65.34M1.81-0.46-73.83%-592.82%-115.42%0.17
IVVDInvivyd, Inc.362.35M1.69-1.18-119.63%-64.32%0.02
SPROSpero Therapeutics, Inc.122.2M2.17-1.71-53.77%-122.56%-165.46%0.09
AVIRAtea Pharmaceuticals, Inc.365.63M4.68-2.34-46.56%0.00

Compare AVIR vs Peers

Analyze head-to-head performance against top industry competitors across valuation, growth, and profitability metrics.

vs BNTX

Compare head-to-head with BioNTech SE

vs MRNA

Compare head-to-head with Moderna, Inc.

Compare Top 5

vs BNTX, MRNA, SMMT, PCVX

Profit & Loss

Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Sales/Revenue+0048.63M351.37M000
Revenue Growth %---622.49%-100%--
Cost of Goods Sold+17K17K38.02M167.21M62.39M70.09M83.37M
COGS % of Revenue--78.18%47.59%---
Gross Profit+-17K-17K10.61M184.16M-62.39M-70.09M-83.37M
Gross Margin %--21.82%52.41%---
Gross Profit Growth %-0%62511.76%1635.74%-133.88%-12.34%-18.94%
Operating Expenses+9.48M14.61M21.64M45.78M68.26M94.07M109.58M
OpEx % of Revenue--44.5%13.03%---
Selling, General & Admin2.8M4.44M21.64M45.78M48.71M49.92M48.85M
SG&A % of Revenue--44.5%13.03%---
Research & Development6.67M10.17M38.02M167.21M88.84M132.84M145.4M
R&D % of Revenue--78.18%47.59%---
Other Operating Expenses00-38.02M-167.21M-69.29M-88.69M-84.67M
Operating Income+-9.48M-14.61M-11.03M138.38M-130.65M-164.16M-192.95M
Operating Margin %---22.68%39.38%---
Operating Income Growth %--54.14%24.49%1354.55%-194.42%-25.65%-17.54%
EBITDA+-9.46M-14.59M-11.01M138.41M-130.39M-163.75M-192.53M
EBITDA Margin %---22.64%39.39%---
EBITDA Growth %--54.24%24.54%1356.98%-194.21%-25.58%-17.58%
D&A (Non-Cash Add-back)17K17K19K29K260K416K416K
EBIT-9.48M-14.61M-11.03M138.38M-111.1M-120.01M-132.22M
Net Interest Income+0574K83K213K029.22M25.49M
Interest Income413K574K83K213K11.15M29.22M25.49M
Interest Expense000011.15M00
Other Income/Expense413K574K83K213K11.15M29.22M25.49M
Pretax Income+-9.06M-14.03M-10.95M138.59M-119.5M-134.94M-167.46M
Pretax Margin %---22.51%39.44%---
Income Tax+00017.4M-3.59M1.02M925K
Effective Tax Rate %100%95.91%100%87.44%97%100.75%100.55%
Net Income+-9.06M-13.46M-10.95M121.19M-115.91M-135.96M-168.38M
Net Margin %---22.51%34.49%---
Net Income Growth %--48.5%18.67%1207.06%-195.64%-17.3%-23.85%
Net Income (Continuing)-9.06M-14.03M-10.95M121.19M-115.91M-135.96M-168.38M
Discontinued Operations0000000
Minority Interest0000000
EPS (Diluted)+-0.90-0.16-0.131.37-1.39-1.63-2.00
EPS Growth %-82.22%18.75%1153.85%-201.46%-17.27%-22.7%
EPS (Basic)-0.90-0.16-0.131.46-1.39-1.63-2.00
Diluted Shares Outstanding10.09M82.62M82.44M88.25M83.25M83.39M84.26M
Basic Shares Outstanding10.09M82.62M82.44M82.82M83.25M83.39M84.26M
Dividend Payout Ratio-------

Balance Sheet

Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Total Current Assets+34.7M21.91M863.48M772.4M660.92M590.46M462.36M
Cash & Short-Term Investments34.49M21.66M850.12M764.38M646.71M578.11M454.72M
Cash Only34.49M21.66M850.12M764.38M646.71M143.82M64.7M
Short-Term Investments00000434.28M390.02M
Accounts Receivable005.82M0000
Days Sales Outstanding--43.64----
Inventory0000000
Days Inventory Outstanding-------
Other Current Assets0249K0014.21M12.35M7.63M
Total Non-Current Assets+163K163K155K489K5.79M4.51M2.31M
Property, Plant & Equipment56K41K48K184K4.09M3.12M2.12M
Fixed Asset Turnover--1013.19x1909.60x---
Goodwill0000000
Intangible Assets0000000
Long-Term Investments107K107K107K0198K00
Other Non-Current Assets015K0305K1.49M1.4M197K
Total Assets+34.86M22.07M863.63M772.89M666.71M594.97M464.67M
Asset Turnover--0.06x0.45x---
Asset Growth %--36.68%3812.62%-10.51%-13.74%-10.76%-21.9%
Total Current Liabilities+1.76M2.44M315.8M56.88M18.48M32.38M18.6M
Accounts Payable391K548K60K4.53M2.55M4.25M4.46M
Days Payables Outstanding8.39K11.77K0.589.914.9222.1419.52
Short-Term Debt0000000
Deferred Revenue (Current)200K200K301.37M0000
Other Current Liabilities200K1.69M11.63M27.57M8.65M07.44M
Current Ratio19.71x9.00x2.73x13.58x35.77x18.24x24.85x
Quick Ratio19.71x9.00x2.73x13.58x35.77x18.24x24.85x
Cash Conversion Cycle-------
Total Non-Current Liabilities+69.26M95K36K5.93M7.66M7.4M7.2M
Long-Term Debt0000000
Capital Lease Obligations00002.4M1.64M842K
Deferred Tax Liabilities0000000
Other Non-Current Liabilities69.26M95K36K5.93M5.25M5.76M6.36M
Total Liabilities71.02M2.53M315.83M62.81M26.14M39.78M25.8M
Total Debt+000197K3.12M2.4M1.64M
Net Debt-34.49M-21.66M-850.12M-764.18M-643.59M-141.42M-63.05M
Debt / Equity---0.00x0.00x0.00x0.00x
Debt / EBITDA---0.00x---
Net Debt / EBITDA----5.52x---
Interest Coverage-----11.72x--
Total Equity+-36.16M19.54M547.8M710.08M640.57M555.19M438.87M
Equity Growth %-154.04%2703.05%29.62%-9.79%-13.33%-20.95%
Book Value per Share-3.580.246.658.057.696.665.21
Total Shareholders' Equity-36.16M19.54M547.8M710.08M640.57M555.19M438.87M
Common Stock10K10K82K83K83K83K84K
Retained Earnings-40.18M-54.21M-65.16M56.03M-59.88M-195.84M-364.22M
Treasury Stock0000000
Accumulated OCI-69.11M0-863.63M0-684K207K233K
Minority Interest0000000

Cash Flow

Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Cash from Operations+-7.91M-12.81M296.73M-87M-120.98M-85.39M-135.5M
Operating CF Margin %--610.15%-24.76%---
Operating CF Growth %--62.04%2415.7%-129.32%-39.05%29.42%-58.67%
Net Income-9.06M-14.03M-10.95M121.19M-115.91M-135.96M-168.38M
Depreciation & Amortization17K17K19K29K260K416K416K
Stock-Based Compensation414K624K7.46M39.62M46.72M49.43M51.77M
Deferred Taxes0-501K0-29.39M0-48.56M0
Other Non-Cash Items538K501K029.39M-5.46M33.11M-11.82M
Working Capital Changes725K579K300.2M-247.84M-46.59M16.16M-7.48M
Change in Receivables00-5.82M0000
Change in Inventory0000000
Change in Payables-90K157K-488K10.29M-1.98M1.7M206K
Cash from Investing+-12K-2K-26K-4K-455.41M40.3M56.1M
Capital Expenditures-12K-2K-26K-4K-1.94M00
CapEx % of Revenue--0.05%0%---
Acquisitions0000453.47K00
Investments-------
Other Investing0000-453.47K00
Cash from Financing+27.48M-15K531.75M1.47M370K257K267K
Debt Issued (Net)0000000
Equity Issued (Net)0-15K1000K1000K230K257K267K
Dividends Paid0000000
Share Repurchases0000000
Other Financing27.48M000140K00
Net Change in Cash19.56M-12.83M828.46M-85.54M-576.02M-44.84M-79.13M
Free Cash Flow+-7.92M-12.82M296.71M-87.01M-122.92M-85.39M-135.5M
FCF Margin %--610.1%-24.76%---
FCF Growth %--61.82%2415.14%-129.32%-41.28%30.53%-58.67%
FCF per Share-0.78-0.163.60-0.99-1.48-1.02-1.61
FCF Conversion (FCF/Net Income)0.87x0.95x-27.11x-0.72x1.04x0.63x0.80x
Interest Paid0000000
Taxes Paid0000000

Key Ratios

Metric2018201920202021202220232024
Return on Equity (ROE)--68.87%-3.86%19.27%-17.16%-22.74%-33.88%
Return on Invested Capital (ROIC)------59.95%-36.66%
Gross Margin--21.82%52.41%---
Net Margin---22.51%34.49%---
Debt / Equity---0.00x0.00x0.00x0.00x
Interest Coverage-----11.72x--
FCF Conversion0.87x0.95x-27.11x-0.72x1.04x0.63x0.80x
Revenue Growth---622.49%-100%--

Deep Dive Analysis

Explore detailed financial history, valuation models, and returns analysis

Valuation Overview

DCF models, peer multiples & analyst estimates

Total Return Calculator

Historical returns with dividends reinvested

Dividend History

Yield, growth, payout safety & DRIP calculator

Earnings History

EPS trends, net income & profitability analysis

Price History

Long-term charts & historical price data

Revenue History

Sales growth patterns & revenue breakdown

Financial Ratios

30 years of valuation, profitability & efficiency metrics

VCP Scanner

Find stocks. Verify deeply. Act with conviction.

Patterns find ideas. Fundamentals build conviction.

Data updated daily

Quick Links

  • Home
  • Screens
  • Valuation
  • Compare
  • Total Return
  • News
  • Insights
  • Methodology
  • How It Works
  • Profile

Popular Screens

  • VCP Hot
  • VCP Warm
  • Value Screens
  • Growth Screens
  • Momentum Screens
  • Technical Screens
  • Quality Screens

Community

  • Twitter
  • Get Early Access
© 2026 VCP Scanner. All rights reserved.
Made with ❤️ for investors
Not financial advice. Do your own research.